AzTrials
AzTrials

Chronic PainNCT07118722

Mindfulness-based Cognitive Therapy vs the Health Enhancement Program for Chronic Pain and Depression; The Quiet Focus Study

A study testing Quiet Focus and Health Enhancement Program in people with Chronic Pain and Depression, run by Massachusetts General Hospital at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to pilot a randomized controlled trial comparing an adaptation of mindfulness-based cognitive therapy to the health enhancement program for chronic pain and depression. Read more about this study

Who is it for?
Ages 50 to 120 years
Conditions the study is for
Chronic Pain, Depression
What is being tested?
Quiet Focus and Health Enhancement Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
1 Sep 2025to 30 Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 120 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Participant Inclusion Criteria

  1. Older adult (age ≥ 50)
  2. All individuals who identify with one or more nationalities or ethnic groups originating in any of the Black racial groups of Africa
  3. Pain in muscles, joints, bones, or associated soft tissues (NRS>4) lasting longer than 3 months
  4. Depressed (PHQ-9 score of 5-14)
  5. English fluency/literacy
  6. Ability and willingness to participate via in-person and video
  7. No change to type or dose of antidepressant medications for at least 6 weeks prior to screening
  8. Willing to provide informed consent and comply with all aspects of the protocol

Participant Exclusion Criteria

  1. Moderately severe or severe depressive symptoms (PHQ-9 ≥ 15)
  2. Current substance abuse/dependence
  3. Significant cognitive impairment
  4. History of more than 8 sessions of cognitive-behavioral therapy
  5. History of previous training in mindfulness or undergoing counseling more than once a month
  6. History of or current diagnosis of psychosis
  7. Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening) or self-harm within the past 90 days
  8. Current participation in another behavioral clinical trial

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tony V Pham contact

United States1 site, 1 recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

    Kelly Horan, 617-726-2000, khoran@mgb.org

    Recruiting

Other trials in United States

About this study

Official title: Mindfulness-Based Cognitive Therapy Adapted for Older Adults At-Risk for the Chronic Pain-Depression Co-Morbidity; The Quiet Focus Pilot Randomized Controlled Trial

The goal of this clinical trial is to pilot a randomized controlled trial comparing an adaptation of mindfulness-based cognitive therapy to the health enhancement program for chronic pain and depression. The main questions it aims to answer in a later fully powered randomized controlled trial are:

  • Is an adaptation of mindfulness-based cognitive therapy for older Black adults able to improve quality of life?
  • Will an adapted mindfulness based cognitive therapy reduce pain interference to a greater degree than a traditional health enhancement program?
Read the detailed description

Co-morbid chronic pain-depression is common among older Black adults and this co-morbidity worsens physical and emotional function. Access to evidence based non-pharmacological management is limited. Mindfulness based cognitive therapy (MBCT) is an evidence-based, non-pharmacological intervention that could address the chronic pain-depression co-morbidity among older Black adults, but it requires tailoring. The proposed study will establish the feasibility, acceptability and credibility of Quiet Focus, a cultural adaptation of MBCT aimed at the chronic pain-depression co-morbidity among older Black adults in the community.

Being tested
Quiet Focus, Health Enhancement Program
Keywords
mindfulness-based cognitive therapy, mind-body, chronic pain, depression, older adult
Medical subject headings
Chronic Pain, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Quiet FocusBehavioural

    Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression

  • Health Enhancement ProgramBehavioural

    Time- and dose-matched control for Quiet Focus.

Study groups in NCT07118722
Study groupRoleWhat they receive
Quiet FocusExperimentalNot described
Receives: Behavioral: Quiet Focus
Health Enhancement ProgramActive comparatorNot described
Receives: Behavioral: Health Enhancement Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The Credibility and Expectancy Questionnaire

    This scale measures participant expectations around the study's positive outcomes, with measures ranging from 0 (not at all expected) to 9 (extremely expected). A higher score indicate greater trust in the study design and an openness to potential benefits.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  2. The Client Satisfaction Questionnaire

    Three item scale measuring patient satisfaction with the program. Scores for each item range from 1 (unsatisfied) to 4 (very satisfied).

    Measured: Administered at the end of treatment at 8 weeks and at the three month follow up visit

  3. Modified Patient Global Impression of Change

    Measures participant impressions of overall change with one being very much improved and eight being very much worse. Lower scores indicate improvement.

    Measured: At end of 8 week program (post test) and again at 3 month follow up visit

Secondary outcomes (11)
  1. Numerical Rating Scale

    Numerical rating of pain with lower scores indicating less pain overall (0 = no pain) and higher scores indicating more pain (10 = worst ever pain) over the past week.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  2. PROMIS Physical Function

    The PROMIS Physical Function raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Unable to do" and 5 = "Without any difficulty," with higher scores indicating better function. This raw score is then converted to a T-score using a standardized table, where 50 represents the average in the general population and 10 is the standard deviation.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  3. PROMIS Depression

    The PROMIS Depression raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores indicating more severe depressive symptoms. This raw score is converted to a T-score using a standardized table, where 50 represents the average level in the general population and 10 is the standard deviation.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  4. PROMIS Anxiety

    The PROMIS Anxiety raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores reflecting greater anxiety symptoms. The raw score is then converted to a T-score using a standardized scoring table, with 50 representing the population average and 10 as the standard deviation.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  5. PROMIS Emotional Support

    The PROMIS Emotional Support raw score is calculated by summing item responses, each rated on a 5-point Likert scale where 1 = "Never" and 5 = "Always," with higher scores indicating greater perceived emotional support. This raw score is converted to a T-score using a standardized table, where 50 represents the average for the general population and 10 is the standard deviation.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  6. Measure of Current Status Part A

    The Measure of Current Status Part A (MOCS-A) is a self-report questionnaire that measures ability to manage stress. The score is calculated by summing responses to each item, rated on a 5-point Likert scale where 0 = "I cannot do this at all" and 4 = "I can do this extremely well," with higher scores reflecting greater confidence in coping skills. The scale measures current perceived ability to manage stress across areas like relaxation, awareness of tension, assertiveness, and coping confidence.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  7. Cognitive and Affective Mindfulness Scale-Revised

    The Cognitive and Affective Mindfulness Scale - Revised (CAMS-R) measures percieved ability to complete mindfulness tasks such as meditation, with a 0 being rarely/not at all and a 3 being almost always. Higher scores indicate greater ability to practice mindfulness skills.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  8. Chronic Pain Acceptance Questionnaire

    The Chronic Pain Acceptance Questionnaire (CPAQ)*= raw score is calculated by summing responses to each item, rated on a 7-point Likert scale where 0 = "Never true" and 6 = "Always true," with higher scores indicating greater acceptance of chronic pain. The scale assesses two key areas: pain willingness(the ability to experience pain without trying to control or avoid it) and activity engagement (continuing meaningful activities despite pain).

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  9. Pain Self-Efficacy Questionnaire

    The Pain Self-Efficacy Questionnaire (PSEQ) measures confidence in engaging in activities despite chronic pain. Higher scores indicate greater confidence (6 = complete confidence) and lower scores indicate lower confidence (0 = not at all confident).

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  10. Pain Catastrophizing Scale

    The Pain Catastrophizing Scale (PCS) score is calculated by summing responses to each item, rated on a 5-point Likert scale where 0 = "Not at all" and 4 = "All the time," with higher scores indicating greater levels of catastrophic thinking related to pain. The scale measures three components of pain catastrophizing: rumination, magnification, and helplessness.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

  11. Tampa Kinesiophobia Scale

    The Tampa Kinesiophobia Scale (TKS) measures fear of movement and is calculated by summing responses to each item, rated on a 4-point Likert scale where 1 = "Strongly disagree" and 4 = "Strongly agree," with higher scores indicating greater fear of movement or reinjury due to physical activity.

    Measured: From enrollment to 3 months from the end of treatment at 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2025
  2. Study start1 Sep 2025
  3. Primary completion15 Jan 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07118722
Sponsor's protocol ID
2025P001670
Other IDs
K23AT012363
Status last verified
Aug 2026
First submitted
31 Jul 2025
Last updated
25 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD collected throughout the trial.

Questions about this trial

What is this clinical trial studying?

A study testing Quiet Focus and Health Enhancement Program in people with Chronic Pain and Depression, run by Massachusetts General Hospital at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tony V Pham (617-800-9988, tonyvpham@mgh.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The Credibility and Expectancy Questionnaire (time frame: From enrollment to 3 months from the end of treatment at 8 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in